Insulin-like growth factor I: Physiology, metabolic effects and clinical uses

Diabetes/Metabolism Reviews

Volumn 12, Issue 3, 1996, Pages 195-215

  Froesch, E Rudolf ^a   Hussain, Mehboob A ^a   Schmid, Christoph ^a   Zapf, Jürgen ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DWARFISM; GLUCOSE METABOLISM; HORMONE DEFICIENCY; HUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; RECOMBINANT PROTEINS;

EID: 0029801897     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199610)12:3<195::AID-DMR164>3.0.CO;2-G     Document Type: Review

References (117)

1. Froesch ER, Bürgi H, Ramseier EB, Bally P, and Labhart A: Antibody-suppressible and nonsuppressible insulin-like activities in human serum and their physiologic significance: an insulin assay with adipose tissue of increased precision and specificity. J Clin Invest 42: 1816-1834, 1963.
2. Rinderknecht E, and Humbel RE: The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 253: 2769-2776, 1978.
3. Salmon WD Jr, and Daughaday WH: A hor- monally controlled serum factor which stimulates sulfate incorporation by cartilage in vivo. J Lab Clin Med 49: 825-836, 1957.
4. Klapper DG, Svoboda ME, and Van Wyk JJ: Sequence analysis of somatomedin C: conformation of identity with insulin-like growth factor I. Endocrinology 112: 2215-2217, 1983.
5. Pierson RW Jr, and Temin HE: The partial purification from calf serum of a fraction with multiplication-stimulating activity for chicken fibroblasts in the cell culture and with non-suppressible insulin-like activity. J Cell Physiol 79: 319-330, 1972.
6. D'Ercole AJ, Stiles AD, and Underwood LE: Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 81: 935-939.
7. Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, and Sinha MK: Insulin-like growth factor-I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal liver. J Clin Invest 81: 976-981, 1988.
8. Zapf J, Schoenle E, Waldvogel M, Sand I, and Froesch ER: Effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors: further evidence for the action of insulin-like growth factors through the insulin receptor. Eur J Biochem 113: 605-609, 1981.
9. Sinha MK, Buchanan C, Leggett N, Martin L, Khazanie PG, Dimarchi R, Pories WJ, and Caro JF: Mechanism of IGF I stimulated glucose transport in human adipocytes: demonstration of specific IGF I receptors not involved in stimulation of glucose transport. Diabetes 38: 1217-1225, 1989.
10. King GL, Kahn CR, Rechler MM, and Nissley SP: Direct demonstration of separate receptors for growth and metabolic activities of insulin and multiplication-stimulating activity (an insulin-like growth factor) using antibodies to the insulin receptor. J Clin Invest 66: 130-140, 1980.
11. Schwander JC, Hauri C, Zapf J, and Froesch ER: Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 113: 297-305, 1983.
12. Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L, and Hintz RL: Somatomedin-C mediates growth hormone negative feedback by effects on both hypothalamus and the pituitary. Science 212: 1279-1281, 1981.
13. Winter RJ, Phillips LS, Klein MN, Traisman HS, and Green OC: Somatomedin activity and diabetic control in children with insulin-dependent diabetes. Diabetes 28: 952-954, 1979.
14. Hall K, Johansson BL, Povoa G, and Thalme B: Serum levels of insulin-like growth factor (IGF) I, II, and IGF binding protein in diabetic adolescents treated with continuous subcutaneous insulin infusion. J Intern Med 225: 273-278, 1989.
15. Lanes R, Recker B, Fort P, and Lifshitz F: Impaired somatomedin generation test in children with insulin-dependent diabetes mellitus. Diabetes 34: 156-160, 1985.
16. Merimee TJ, Zapf J, and Froesch ER: Insulin-like growth factors in the fed and fasted states. J Clin Endocrinol Metab 55: 999-1002, 1992.
17. Leahy JL, and Vanderkerkhove KM: Insulin-like growth factor at physiological concentrations is a potent inhibitor of insulin secretion. Endocrinology 126: 1593-1598, 1990.
18. Guler HP, Schmid C, Zapf J, and Froesch ER: Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 86: 2868-2872, 1989.
19. Zenobi PD, Graf S, Ursprung H, and Froesch ER: Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. J Clin Invest 89: 1908-1913, 1992.
20. Rennert NJ, Caprio S, and Sherwin RS: Insulin-like growth factor I inhibits glucose stimulated insulin secretion but does not impair glucose metabolism in normal humans. J Clin Endocrinol Metab 76: 804-806, 1993.
21. Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, and Froesch ER: Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in man. J Clin Invest 92: 2249-2256, 1993.
22. Baxter R: Circulating binding proteins of insulin-like growth factors. Trends Endocrinol Metab 4: 91-96.
23. Laron Z, Anin S, Klipper-Aurbach Y, and Klinger B: Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 339: 1258-1261, 1992.
24. Walker JL, van Wyk JJ, and Underwood LE: Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron-type). J Pediatr 121: 641-646, 1992.
25. Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB Jr, Gargosky SE, Nonoshita L, and Rosenfeld RG: A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 80: 1393-1398, 1995.
26. Scheiwiller E, Guler H-P, Merryweather J, Scandella C, Maerki W, Zapf J, and Froesch ER: Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I. Nature 323: 169-171, 1986.
27. Efstratiadis A: IGFs and dwarf mice: genetic and epigenetic control of embryonic growth. In Developmental Endocrinology, Vol 6, Sizonenko PC, Aubert ML, and Vassalli J-D (Eds). Ares-Serono Symposia Publications - Frontiers in Endocrinology, Raven Press, New York 1994, p. 27.
28. Roback EW, Barakat AJ, Dev VG, Mbikay M, Chretien M, and Butler MG: An infant with deletion of the distal long arm of chromosome 15 (q26.1-qter) and loss of insulin-like growth factor I receptor gene. Am J Med Genet 38: 74-79, 1991.
29. Rabinowitz DK, and Zierler L: A metabolic regulation device based on the actions of human growth hormone and of insulin, singly and together, on the human forearm. Nature 199: 913-914, 1963.
30. Brand Miller JC, and Colagiuri S: The carnivore connection: dietary carbohydrate in the evolution of NIDDM. Diabetologia 37: 1280-1286, 1994.
31. Neel JV: Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 14: 353-362, 1962.
32. Zapf J, Futo E, Peter M, and Froesch ER: Can "big" IGF II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia (EPTH)? J Clin Invest 90: 2574-2584, 1992.
33. Daughaday WH, Hall K, Raben MS, Salmon WD Jr, van den Brande JL, and van Wyk JJ: Somatomedin: proposed designation for sulfation factor. Nature 235: 107, 1972.
34. Bar RS, Clemmons DR, Boes M, Busby WH, Booth BA, Dake BL, and Sandra A: Transcapillary permeability and subendothelial distribution of endothelial and amniotic fluid insulin-like growth factor binding proteins in the rat heart. Endocrinology 127: 1078-1086, 1990.
35. Zapf J, Hauri C, Waldvogel M, and Froesch ER: Acute metabolic effects and half-lives of intravenously administered insulin-like growth factors I and II in normal and hypophysectomized rats. J Clin Invest 77: 1768-1775, 1986.
36. Oelz O, Jakob A, and Froesch ER: Nonsuppressible insulin-like activity (NSILA) of human serum. V. Hypoglycaemia and preferential metabolic stimulation of muscle by NSILA-S. Eur J Clin Invest 1: 48-53, 1970.
37. Froesch ER, Müller WA, Bürgi H, Waldvogel M, and Labhart A: Non-suppressible insulin-like activity of human serum. II. Biological properties of plasma extracts with non-suppressible insulin-like activity. Biochim Biophys Acta 121: 360-374, 1966.
38. Guler HP, Zapf J, and Froesch ER: Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317: 137-140, 1987.
39. Boulware SD, Tamborlane WV, Matthews LS, and Sherwin RS: Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acids. Am J Physiol 262: E130-133, 1992.
40. Turkalj I, Keller U, Ninnis R, Vosmeer S, and Stauffacher W: Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J Clin Endocrinol Metab 75: 1186-1191, 1992.
41. Jacob R, Barrett E, Plewe G, Fagin KD, and Sherwin RS: Acute effects of insulin-like growth factor I on glucose and amino acid metabolism in the awake fasted rat. J Clin Invest 83: 1717-1723, 1989.
42. Laager R, Ninnis R, and Keller U: Comparison of the effects of rhIGF-I and insulin on glucose and leucine kinetics in man. J Clin Invest 92: 1903-1909, 1993.
43. Moller J, Jorgensen JO, Moller N, Christiansen JS, and Weeke J: Effects of growth hormone administration on fuel oxidation and thyroid function in normal man. Metabolism 41: 728-731, 1992.
44. Hussain MA, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J, and Froesch ER: Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J Clin Invest 94: 1126-1133, 1994.
45. Salomon F, Cuneo RC, Hesp R, and Sonksen PH: The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321: 1797-1803, 1989.
46. Mauras N, Horber FF, and Haymond MW: Low dose recombinant human insulin-like growth factor-I fails to affect protein anabolism but inhibits islet cell secretion in humans. J Clin Endocrinol Metab 75: 1192-1197, 1992.
47. Douglas RG, Gluckman PD, Ball K, Breier B, and Shaw JH: The effects of infusion of insulin-like growth factor (IGF) I, IGF II, and insulin on glucose and protein metabolism in fasted lambs. J Clin Invest 88: 614-622, 1991.
48. Hussain MA, Schmitz O, Riesen W, Steinmann B, Christiansen JS, Zapf J, and Froesch ER: Five day treatment with IGF I alters circulating lipid and amino acid profiles in healthy man (Abstract). Growth Regul 4 (Suppl 1): 152, 1994.
49. Zenobi PD, Jaeggi-Groisman SE, Riesen W, Roder M, and Froesch ER: Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 90: 2234-2241, 1992.
50. Zenobi PD, Holzmann P, Glatz Y, Riesen WF, and Froesch ER: Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I. Diabetologia 36: 465-469, 1993.
51. Scanu AM: Lipoprotein (a): a genetic risk factor for premature coronary heart disease. JAMA 267: 3326-3329, 1992.
52. Oscarsson J, Lundstam U, Gustafsson B, Wilton P, Edén S, and Wiklund O: Recombinant human insulin-like growth factor-I decreases serum lipoprotein (a) concentrations in normal adult men. Clin Endocrinol 42: 673-676, 1995.
53. Kades WW, Elsewafay SA, Ayad MF et al: Low-doses of insulin-like growth factor-I (IGF-I) improve insulin sensitivity (Abstract 381). Diabetes 43 (Suppl 1), 1994.
54. Bar RS, Harrison LC, Muggeo M, Gorden P, Kahn CR, and Roth J: Regulation of insulin receptors in normal and abnormal physiology in humans. Adv Intern Med 24: 23-52, 1979.
55. Sherwin RS, Hendler RG, and Felig F: Effect of growth hormone on oral glucose tolerance and circulating metabolic fuels in man. Diabetologia 24: 155-161, 1983.
56. Cheetham TD, Jones J, Taylor AM, Holly J, Matthews DR, and Dunger DB: The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36: 678-681, 1993.
57. Dunger DB: IGF-I treatment of type I diabetic subjects. Presented at the annual meeting of the European Society of Clinical Investigation, Toledo, Spain, 20-23 April, 1994.
58. Kiowski W, Stoschitzky K, Kim JH, Hussain MA, and Froesch ER: Insulin-like growth factor-I causes endothelium-dependent arterial vasodilation (Abstract 1298). Circulation 90: 1-242, 1994.
59. Guler H-P, Eckardt K-U, Zapf J, Bauer C, and Froesch ER: Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man. Acta Endocrinol (Copenh) 121: 101-106, 1989.
60. Franzeck UK, Dörffler-Melly J, Hussain MA, Wen S, Froesch ER, and Bollinger A: Effects of subcutaneous insulin-like growth factor-I infusion on skin microcirculation. Int J Microcirc 15: 10-13, 1995.
61. Schoenle E, Zapf J, Humbel RE, and Froesch ER: Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature (Lond) 323: 169-171, 1982.
62. Van-Buul-Offers S, Ueda I, and Van den Brande JL: Biosynthetic somatomedin C (SM-C/IGF-I) increases the length and weight of Snell dwarf mice. Pediatr Res 20: 825-827, 1986.
63. Guler H-P, Zapf J, Scheiwiller E, and Froesch ER: Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci USA 85: 4889-4893, 1988.
64. Walker JL, Ginalska-Malinowska M, Romer TE, Pucilowska JB, and Underwood LE: Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism). N Engl J Med 324: 1483-1488, 1991.
65. Laron Z, Anin S, Klipper-Aurbach Y, and Klinger B: Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 339: 1258-1261, 1992.
66. Wilton P: Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndromes). Acta Paediatr Scand Suppl 383: 137-141, 1992.
67. Malozowski S, Tanner LA, Wysowski D, and Fleming GA: Growth hormone, insulin-like growth factor, and benign intracranial hypertension. N Engl J Med 329: 665-666, 1993.
68. Ziegler TR, Young LS, Manson JM, and Wilmore DW: Metabolic effects of recombinant human growth hormone in patients receiving parenteral nutrition. Ann Surg 208: 6-16, 1988.
69. Snyder DK, Clemmons DR, and Underwood LE: Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis and body composition. J Clin Endocrinol Metab 67: 54-61, 1988.
70. Ward HC, Halliday D, and Sim AJW: Protein and energy metabolism with biosynthetic human growth hormone after gastrointestinal surgery. Ann Surg 206: 56-61, 1987.
71. Horber FF, and Haymond MW: Human growth hormone prevents protein catabolic side effects of prednisone in humans. J Clin Invest 86: 265-272, 1990.
72. Dahn MS, Lange MP, and Jacobs LA: Insulin-like growth factor-I production is inhibited in human sepsis. Arch Surg 123: 1409-1414, 1988.
73. Suh DY, Hunt TK, and Spencer ME: Insulin-like growth factor-I reverses the impairment of wound healing induced by corticosteroids in rats. Endocrinology 131: 2399-2403, 1992.
74. Clemmons DR, Smith-Banks A, and Underwood LE: Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J Clin Endocrinol Metab 75: 234-238, 1992.
75. Kupfer SR, Underwood LE, Baxter RC, and Clemmons DR: Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by the use of both agents simultaneously. J Clin Invest 91: 391-396, 1993.
76. Hirschberg R, Kopple JD, Blantz RC, and Tucker BJ: Effects of recombinant human insulin-like growth factor I on glomerular dynamics in the rat. J Clin Invest 87: 1200-1206, 1991.
77. Hirschberg R, and Kopple JD: Response of insulin-like growth factor I and renal hemodynamics to a high- and low-protein diet in the rat. J Am Soc Nephrol 1: 1034-1040, 1991.
78. Hirschberg R, Brunori G, Kopple JD, and Guler HP: Effects of insulin-like growth factor I on renal function in normal men. Kidney Int 43: 387-397, 1993.
79. Miller SB, Martin DR, Kissane J, and Hammerman MR: Hepatocyte growth factor accelerates recovery from acute ischemic renal injury in rats. Am J Physiol 266: F129-134, 1994.
80. Rogers SA, Miller SB, and Hammerman MR: Enhanced renal IGF I expression following partial kidney infarction. Am J Physiol 264: F963-967, 1993.
81. Hammerman MR, O'Shea M, and Miller SB: Role of growth factors in regulation of renal growth. Ann Rev Physiol 55: 305-321, 1993.
82. Miller SB, Martin DR, Kissane J, and Hammerman MR: Insulin-like growth factor I accelerates recovery from ischemic acute tubular necrosis in the rat. Proc Natl Acad Sci USA 89: 11876-11880, 1992.
83. Ding H, Kopple JD, Cohen A, and Hirschberg R: Recombinant human insulin-like growth factor-I accelerates recovery and reduces catabolism in rats with ischemic acute renal failure. J Clin Invest 91: 2281-2287, 1993.
84. Miller SB, Martin DR, Kissane J, and Hammerman MR: Rat models for clinical use of insulin-like growth factor I in acute renal failure. Am J Physiol 266: F949-956, 1994.
85. O'Shea MH, Miller SB, and Hammerman MR: Effects of IGF I on renal function in patients with chronic renal failure. Am J Physiol 264: F917-922, 1993.
86. Zenobi PD, Hussain MA, Lehmann R, Glatz Y, Keller A, and Froesch ER: Insulin demand in type I diabetes mellitus is reduced during administration of insulin-like growth factor-I (Abstract 249). Diabetologia 35 (Suppl 1), 1992.
87. Reaven GM: Banting lecture 1988: role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988.
88. Schalch DS, Turman NJ, Marcsisin VS, Heffernan M, and Guler HP: Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus. J Clin Endocrinol Metab 77: 1563-1568, 1993.
89. Young CJ, and Clemmons DR: Changes in insulin-like growth factor (IGF)-binding proteins after IGF-I injections on non-insulin-dependent diabetics. J Clin Endocrinol Metab 79: 609-614, 1994.
90. Moller DE, and Flier JS: Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med 325: 938-948, 1991.
91. Schoenle EJ, Zenobi PD, Toressani T, Werder EA, Zachmann M, and Froesch ER: Recombinant human insulin-like growth factor I (rhIGF-I) reduces hyperglycemia in patients with extreme insulin resistance. Diabetologia 34: 675-679, 1991.
92. Quin JD, Fisher BM, Paterson KR, Inoue A, Beastall GH, and MacCuish AC: Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome. N Engl J Med 323: 1425-1426, 1990.
93. Hussain MA, and Froesch ER: Treatment of type A insulin resistance with insulin-like growth factor-I. Lancet 341: 1536-1537, 1993.
94. Zenobi PD, Glatz Y, Keller A, Graf S, Jaeggi-Groisman SE, Riesen WF, Schoenle EJ, and Froesch ER: Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol 131: 251-257, 1994.
95. Kuzuya H, Masuura N, Sakamoto M et al: Trial of insulin-like growth factor I therapy in pat- ients with extreme insulin resistance syndromes. Diabetes 42: 696-705, 1993.
96. Hone J, Skarulis MC, Roach P et al: IGF I treatment of severely insulin-resistant child with short stature and diabetes mellitus (Abstract 1319). Presented at the 76th Annual Endocrine Society Meeting, Anaheim 1994.
97. Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA, and Skarulis M: Clinical uses of insulin-like growth factor I. Ann Intern Med 120: 593-601, 1994.
98. Bennett AE, Wahner HW, Riggs BL, and Hintz RL: Insulin-like growth factors I and II: aging and bone mineral density in women. J Clin Endocrinol Metab 59: 701-704, 1984.
99. Johansson AG, Forslund A, Hambraeus L, Blum WF, and Ljunghall S: Growth hormone-dependent insulin-like growth factor binding protein is a major determinant of bone mineral density in healthy men. J Bone Min Res 9: 915-921, 1994.
100. Kaufmann JL, Taelman P, Vermeulen A, and Vandeweghe M: Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 74: 118-123, 1992.
101. Rosen T, Hansson T, Granhed H, Szucs J, and Bengtsson BA: Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 129: 201-206, 1993.
102. Schlemmer A, Johansen JS, Pedersen SA, Jörgensen JO, Hassager C, and Christiansen C: The effect of growth hormone therapy on urinary pyridinoline cross-links in GH-deficient adults. Clin Endocrinol 35: 471-476, 1991.
103. Johansen JS, Pedersen SA, Jorgensen JOL, Rjis BJ, Christiansen C, Christiansen JS, and Skakkebaek NE: Effects of growth hormone on plasma bone GIa protein in GH-deficient adults. J Clin Endocrinol Metab 70: 916-919, 1990.
104. Binnerts A, Swart GR, Wilson PJH, Hoogerbrugge N, Pols HAP, Birkenhager JC, and Lamberts SWJ: The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis as well as on body composition. Clin Endocrinol 37: 79-87, 1992.
105. Bengtsson BA, Eden S, Lönn L, Kvist H, Stockland A, Lindstedt G, Bosaeus I, Tölli J, Sjöström L, and Isaksson OGP: Treatment of adults with growth hormone deficiency with recombinant human growth hormone. J Clin Endocrinol Metab 76: 309-317, 1993.
106. Beshyah SA, Thomas E, Kyd P, Sharp P, Fairney A, and Johnston DG: The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism. Clin Endocrinol 40: 383-391, 1994.
107. Balducci R, Toscano F, Pasquino AM, Mangiantini A, Municchi G, Armenise P, Terracina S, Prossomariti G, and Boscherini B: Bone turnover and bone mineral density in young adult patients with panhypopituitarism before and after long-term growth hormone therapy. Eur J Endocrinol 132: 42-46, 1995.
108. Holmes SJ, Whitehouse RW, Swindell R, Economou G, Adams JE, and Shalet SM: Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. Clin Endocrinol 42: 627-633, 1995.
109. Ebeling PR, Jones JD, O'Fallon WM, Janes CH, and Riggs B: Short term effects of recombinant human insulin-like growth factor-I on bone turnover in normal women. J Clin Endocrinol Metab 77: 1384-1387, 1993.
110. 3 production in healthy man. J Int Med (submitted).
111. Brixen K, Nielsen HK, Mosekilde L, and Flyvbjerg A: A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Min Res 5: 609-618, 1990.
112. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, and Mattson DE: Effects of human growth hormone in men over 60 years old. N Engl J Med 323: 1-6, 1990.
113. Holloway L, Butterfield GE, Hintz RL, Gesundheit N, and Marcus R: Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 79: 470-479, 1994.
114. Johansson AG, Lindh E, and Ljunghall S: IGFs: function and clinical importance. 4. Growth hormone, insulin-like growth factor I and bone: a clinical review. J Intern Med 234: 553-560, 1993.
115. Parfitt AM: Growth hormone and adult bone remodelling. Clin Endocrinol 35: 467-470, 1991.
116. Johansson AG, Lindh E, and Ljunghall S: Insulin-like growth factor-I stimulates bone turnover in osteoporosis. Lancet 339: 1619, 1992.
117. Rubin CD, Reed B, Sakhace K, and Pak CYC: Treating a patient with the Werner syndrome and osteoporosis using recombinant human insulin-like growth factor. Ann Intern Med 121: 665-668, 1994.